SC-β Cell Differentiation Composition for Higher GSIS
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The scarcity and quality of donor islets limit the therapeutic potential of pancreatic β-cell transplantation for diabetes, and existing methods for generating stem cell-derived β-cells are inefficient in producing functional pancreatic progenitor cells and β-cells with adequate glucose-stimulated insulin secretion.
Innovation Solution
A method involving contacting Pdx1-negative, NKX6.1-negative primitive gut tube cells with a BMP signaling pathway inhibitor and a growth factor from the TGF-β superfamily to generate Pdx1-positive, NKX6.1-positive pancreatic progenitor cells, followed by differentiation into insulin-positive endocrine cells and pancreatic β-cells, enhancing glucose-stimulated insulin secretion.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If cadaveric human islets are used for transplantation, then patients can be made insulin independent for 5 years or longer, but the scarcity and quality of donor islets limits the therapeutic potential
Solution Approach 1:
The patent creates functional copies of native pancreatic β-cells by differentiating stem cells into pancreatic progenitor cells that express key markers (Pdx1, NKX6.1, INS, HNF1A) and exhibit glucose-stimulated insulin secretion, providing unlimited supply without relying on scarce donor islets
Solution Approach 2:
The patent changes the source from natural donor islets to stem cell-derived progenitor cells, fundamentally altering the production parameters to enable unlimited scalability while maintaining functional characteristics necessary for insulin independence
2Quantity of substance
If existing stem cell-derived β-cell methods are used, then unlimited supply can be generated, but the methods are inefficient in producing functional pancreatic progenitor cells with adequate glucose-stimulated insulin secretion
Solution Approach 1:
The patent optimizes differentiation parameters by using specific growth factors (FGF2, VEGF, EGF, bFGF) and signaling pathway modulators (BMP inhibitors, TGF-β activators) to enhance the efficiency of producing functional progenitor cells with adequate glucose-stimulated insulin secretion
Solution Approach 2:
The patent introduces intermediate signaling pathway modulators (BMP inhibitors like LDN-193189, TGF-β activators like Activin A) that facilitate efficient differentiation from stem cells to functional pancreatic progenitor cells, acting as mediators that bridge the gap between unlimited supply potential and functional productivity
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method produces pancreatic β-cells with a higher glucose-stimulated insulin secretion index and increased cell density, addressing the inefficiencies of existing methods and providing a potential therapeutic solution for diabetes.
Implementation Method 1
contacting a population of Pdx1-negative, NKX6.1-negative primitive gut tube cells with a composition comprising a bone morphogenetic protein (BMP) signaling pathway inhibitor and a growth factor from transformation growth factor β (TGF-β) superfamily
Implementation Method 2
a growth factor from transformation growth factor β (TGF-β) superfamily
Implementation Method 3
differentiating the PDX1-positive/NKX6.1-negative pancreatic progenitor cells into pancreatic β cells... differentiating the insulin-positive endocrine cells into pancreatic β cells... cell cluster comprising non-native pancreatic β cells has a glucose-stimulated insulin secretion (GSIS) stimulation index higher than a comparable cell cluster
Data Source
AI summary
Disclosed herein are compositions and methods useful for manufacturing SC-β cell, and isolated populations of SC-β cells for use in various applications, such as cell therapy.